Myriad says GeneSight Psychotropic Test led to fewer hospitalizations in study

Myriad Genetics (MYGN) announced that the Journal of Clinical Psychopharmacology has published a study showing those with major depressive disorder had fewer psychiatric hospitalizations after taking the GeneSight Psychotropic Test. The publication includes additional analysis of the study results first shared at the 2024 American Association of Psychiatric Pharmacists conference. The study, entitled “Real-World Impact of Pharmacogenomic Testing on Medication Use and Healthcare Resource Utilization in Patients with Major Depressive Disorder,” showed, following GeneSight testing: There was an almost 40% relative reduction in the proportion of patients who filled prescriptions with significant gene-drug interactions. The company believes these data suggest that healthcare providers are using the GeneSight test to inform treatment decisions. A 39% relative reduction in psychiatric-related hospitalizations and a 29% relative reduction in hospitalizations for any reason were observed. Patients who were switched to medications with no/moderate gene-drug interactions had a 44% relative reduction in psychiatric hospitalizations and a 34% relative reduction in hospitalizations for any reason.